Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Journal Of Acquired Immune Deficiency Syndromes (1999)
Johnson, Margaret M; Kumar, Princy P; Molina, Jean-Michel JM; Rizzardini, Giuliano G; Cahn, Pedro P; Bickel, Markus M; Mallolas, Josep J; Zhou, Yan Y; Morais, Cristiana C; Kumar, Sushma S; Sklar, Peter P; Hanna, George J GJ; Hwang, Carey C; Greaves, Wayne W; ,
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America
Orkin, Chloe C; Squires, Kathleen E KE; Molina, Jean-Michel JM; Sax, Paul E PE; Wong, Wing-Wai WW; Sussmann, Otto O; Kaplan, Richard R; Lupinacci, Lisa L; Rodgers, Anthony A; Xu, Xia X; Lin, Gina G; Kumar, Sushma S; Sklar, Peter P; Nguyen, Bach-Yen BY; Hanna, George J GJ; Hwang, Carey C; Martin, Elizabeth A EA; ,